CUV 0.54% $14.66 clinuvel pharmaceuticals limited

Ann: CLINUVEL Newsletter III - June 2024, page-32

  1. 594 Posts.
    lightbulb Created with Sketch. 281
    I now see that Palatin has commenced a P2 trial for ED (n=50, topline results 6/12). Palatin are trialling MT2 for ED and weight loss. both in combination with PDE5i and GLP1 drugs. Weight loss, frying pan handle boners, if only there was a way of getting a tan. The ultimate barbie drug.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.